Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 28

1.

In-hospital statin underutilization among high-risk patients: delayed uptake of the 2013 cholesterol guidelines in a U.S. cohort.

Wadia SK, Belkin M, Chow KS, Nattiv J, Appis A, Feinstein SB, Williams KA Sr.

Hosp Pract (1995). 2017 Feb;45(1):16-20. doi: 10.1080/21548331.2017.1282798.

PMID:
28092990
2.

Patterns of Statin Use in a Real-World Population of Patients at High Cardiovascular Risk.

Lin I, Sung J, Sanchez RJ, Mallya UG, Friedman M, Panaccio M, Koren A, Neumann P, Menzin J.

J Manag Care Spec Pharm. 2016 Jun;22(6):685-98. doi: 10.18553/jmcp.2016.22.6.685.

3.

Comparative effects of more versus less aggressive treatment with statins on the long-term outcome of patients with acute ischemic stroke.

Tziomalos K, Giampatzis V, Bouziana SD, Spanou M, Kostaki S, Papadopoulou M, Angelopoulou SM, Konstantara F, Savopoulos C, Hatzitolios AI.

Atherosclerosis. 2015 Nov;243(1):65-70. doi: 10.1016/j.atherosclerosis.2015.08.043. Epub 2015 Sep 2.

PMID:
26355807
4.

Secreted Frizzled Related Protein 3 in Chronic Heart Failure: Analysis from the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA).

Askevold ET, Gullestad L, Nymo S, Kjekshus J, Yndestad A, Latini R, Cleland JG, McMurray JJ, Aukrust P, Ueland T.

PLoS One. 2015 Aug 19;10(8):e0133970. doi: 10.1371/journal.pone.0133970. eCollection 2015.

5.

Telomere length and outcomes in ischaemic heart failure: data from the COntrolled ROsuvastatin multiNAtional Trial in Heart Failure (CORONA).

Haver VG, Mateo Leach I, Kjekshus J, Fox JC, Wedel H, Wikstrand J, de Boer RA, van Gilst WH, McMurray JJ, van Veldhuisen DJ, van der Harst P.

Eur J Heart Fail. 2015 Mar;17(3):313-9. doi: 10.1002/ejhf.237. Epub 2015 Feb 2.

6.

The impact of coronary artery disease risk loci on ischemic heart failure severity and prognosis: association analysis in the COntrolled ROsuvastatin multiNAtional trial in heart failure (CORONA).

Haver VG, Verweij N, Kjekshus J, Fox JC, Wedel H, Wikstrand J, van Gilst WH, de Boer RA, van Veldhuisen DJ, van der Harst P.

BMC Med Genet. 2014 Dec 21;15:140. doi: 10.1186/s12881-014-0140-3.

7.

Novel extracellular matrix biomarkers as predictors of adverse outcome in chronic heart failure: association between biglycan and response to statin therapy in the CORONA trial.

Ueland T, Aukrust P, Nymo SH, Kjekshus J, McMurray JJ, Wikstrand J, Block D, Zaugg C, Gullestad L.

J Card Fail. 2015 Feb;21(2):153-9. doi: 10.1016/j.cardfail.2014.10.016. Epub 2014 Nov 7.

PMID:
25451704
8.

Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: rationale and design of the ODYSSEY outcomes trial.

Schwartz GG, Bessac L, Berdan LG, Bhatt DL, Bittner V, Diaz R, Goodman SG, Hanotin C, Harrington RA, Jukema JW, Mahaffey KW, Moryusef A, Pordy R, Roe MT, Rorick T, Sasiela WJ, Shirodaria C, Szarek M, Tamby JF, Tricoci P, White H, Zeiher A, Steg PG.

Am Heart J. 2014 Nov;168(5):682-9. doi: 10.1016/j.ahj.2014.07.028. Epub 2014 Aug 7.

9.

Predictive value of endostatin in chronic heart failure patients with poor kidney function.

Ueland T, Aukrust P, Nymo SH, Kjekshus J, McMurray JJ, Wikstrand J, Wienhues-Thelen UH, Block D, Zaugg C, Gullestad L.

Cardiology. 2015;130(1):17-22. doi: 10.1159/000368220. Epub 2014 Nov 22.

PMID:
25428583
10.

Rosuvastatin reduces ischemia-reperfusion injury in patients with acute coronary syndrome treated with percutaneous coronary intervention.

Jiang F, Yang J, Zhang L, Li R, Zhuo L, Sun L, Zhao Q.

Clin Cardiol. 2014 Sep;37(9):530-5. doi: 10.1002/clc.22292. Epub 2014 Aug 25.

11.

Prognostic effect of high-sensitive troponin T assessment in elderly patients with chronic heart failure: results from the CORONA trial.

Gravning J, Askevold ET, Nymo SH, Ueland T, Wikstrand J, McMurray JJ, Aukrust P, Gullestad L, Kjekshus J; CORONA Study Group.

Circ Heart Fail. 2014 Jan;7(1):96-103. doi: 10.1161/CIRCHEARTFAILURE.113.000450. Epub 2013 Nov 27.

12.

Soluble glycoprotein 130 predicts fatal outcomes in chronic heart failure: analysis from the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA).

Askevold ET, Nymo S, Ueland T, Gravning J, Wergeland R, Kjekshus J, Yndestad A, Cleland JG, McMurray JJ, Aukrust P, Gullestad L.

Circ Heart Fail. 2013 Jan;6(1):91-8. doi: 10.1161/CIRCHEARTFAILURE.112.972653. Epub 2012 Dec 10.

13.
14.

The predictive value of galectin-3 for mortality and cardiovascular events in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA).

Gullestad L, Ueland T, Kjekshus J, Nymo SH, Hulthe J, Muntendam P, McMurray JJ, Wikstrand J, Aukrust P.

Am Heart J. 2012 Dec;164(6):878-83. doi: 10.1016/j.ahj.2012.08.021. Epub 2012 Oct 29.

PMID:
23194488
15.

Soluble ST2 is associated with adverse outcome in patients with heart failure of ischaemic aetiology.

Broch K, Ueland T, Nymo SH, Kjekshus J, Hulthe J, Muntendam P, McMurray JJ, Wikstrand J, Cleland JG, Aukrust P, Gullestad L.

Eur J Heart Fail. 2012 Mar;14(3):268-77. doi: 10.1093/eurjhf/hfs006. Epub 2012 Feb 2.

16.

[Inflammation and lipids in the coronary pathology. Risk factors, causes or therapeutic target?].

Filardi PP, Cecere M, Savarese G, Damore C, Parente A, Conte S, Coutsoumbas G.

G Ital Cardiol (Rome). 2010 Dec;11(12 Suppl 3):10S-15S. Italian.

PMID:
21491734
17.

Osteoprotegerin predicts progression of chronic heart failure: results from CORONA.

Ueland T, Dahl CP, Kjekshus J, Hulthe J, Böhm M, Mach F, Goudev A, Lindberg M, Wikstrand J, Aukrust P, Gullestad L.

Circ Heart Fail. 2011 Mar;4(2):145-52. doi: 10.1161/CIRCHEARTFAILURE.110.957332. Epub 2011 Jan 7.

19.

12-month follow-up results of high dose rosuvastatin loading before percutaneous coronary intervention in patients with acute coronary syndrome.

Yun KH, Oh SK, Rhee SJ, Yoo NJ, Kim NH, Jeong JW.

Int J Cardiol. 2011 Jan 7;146(1):68-72. doi: 10.1016/j.ijcard.2010.04.052. Epub 2010 May 14.

PMID:
20471117

Supplemental Content

Loading ...
Support Center